MicroFAST Dx specializes in upstream sample collection and processing innovations, including rapid plasma separation without centrifugation and centrifuge-free DNA extraction. These technologies enable decentralized processing to support assays and molecular tests at the point of need, thereby streamlining diagnostic workflows for both laboratory and point-of-care settings.
The division’s flagship efforts include the development of devices such as RapiSep, designed to convert whole blood to plasma with minimal training and in diverse environments. By partnering with in vitro diagnostics (IVD) developers and direct-to-consumer diagnostic companies, MicroFAST Dx aims to enhance accessibility, patient privacy, and convenience in blood-based testing, reducing barriers associated with traditional clinical visits.
“Establishing MicroFAST Dx allows us to accelerate the commercialization of our rapid sample processing platforms,” said Jason Zhou, CEO of Zymeron Corporation and Interim CEO of MicroFAST Dx. “This dedicated structure positions us to better serve the growing demand for user-friendly, decentralized diagnostics that empower individuals and healthcare providers alike.”
About Zymeron
For more information, please visit www.zymeron.com or www.microfastdx.com.
Zymeron (www.zymeron.com) is a research-based biotechnology company discovering and developing innovations to enable breakthrough performance in proactive health technologies. Zymeron is an innovation engine enabling innovators to move ideas out of the lab and into the market through product-specific new ventures.